The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

Your health history, medication use, and any recent infections will also be assessed. Depending on your symptoms and conditions, you may be diagnosed with one of many types of psoriasis, from plaque ...

A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients ...

Introduction. Current management guidelines for rheumatoid arthritis (RA) and psoriatic arthritis (PsA) recommend a treat-to-target (T2T) approach.1 2 In a T2T approach, treatment is adjusted if the ...

Psoriasis and rheumatoid arthritis are both autoimmune conditions, and it’s possible to have both at once. It’s more common to have psoriatic arthritis along with psoriasis.

Objective To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). Methods In this double-blind, ...

For example, my mother has psoriasis, my two siblings and I have psoriasis, and one out of three of my daughters has shown signs of psoriasis—all on our scalp, and I sometimes get it on my face in ...

Objective To determine the contribution of clinical and biochemical inflammation to structural progression of patients with psoriatic arthritis (PsA).Methods We analysed patients from the Infliximab ...

The European Medicines Agency’s human medicines committee (CHMP) adopted positive opinions for six biosimilar medicines at its June meeting.

Psoriatic disease is a long-term (chronic) disease with, thus far, no known cure. The good news, however, is that there are ...